<DOC>
	<DOCNO>NCT02117050</DOCNO>
	<brief_summary>This Phase IV , prospective , open-label , multi-center trial ass treatment satisfaction patient relapse form Multiple Sclerosis ( MS ) currently treat , consider discontinue treatment Tecfidera™ .</brief_summary>
	<brief_title>RESOunD : REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key inclusion Criteria : Diagnosis relapse form MS Have declare desire/plan discontinue treatment Tecfidera due tolerability issue and/or lack efficacy Expanded Disability Status Scale ( EDSS ) score 0 5.0 inclusive Other protocol define inclusion criterion could apply Key exclusion Criteria : Pregnant lactate Significant renal hepatic impairment significant disease would compromise adherence completion trial Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Rebif ®</keyword>
	<keyword>Tecfidera ™</keyword>
	<keyword>treatment change</keyword>
</DOC>